Literature DB >> 7962603

Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

G Saccani Jotti1, S R Johnston, J Salter, S Detre, M Dowsett.   

Abstract

AIM: To validate the use of a new mouse monoclonal antibody (1D5) directed against the N-terminal domain (A/B region) of the oestrogen receptor in an immunohistochemical assay (ER-IHA) for paraffin wax embedded tissue.
METHODS: Breast cancer specimens were surgically obtained from 119 previously untreated patients. For comparison, oestrogen receptor was measured from cytosol fractions using an established oestrogen receptor enzyme immunoassay (ER-EIA) method. Oestrogen receptor "H-scores" were obtained from the ER-IHA after antigen retrieval using microwave treatment. Where discrepancies occurred between the two methods, further immunohistochemistry was performed using the H222 antibody from the Abbott Laboratories ER-ICA kit.
RESULTS: The correlation between the two methods was non- linear, but despite this there was an 86% concordance between ER-EIA and ER-IHA using the 1D5 ER antibody. Fifty four per cent of tumours (64/119) were oestrogen receptor positive and 32% (38/119) were negative by both assays. A mismatch between the ER-EIA and ER-IHA occurred in 17 cases. Seven tumours were IHA positive but EIA+, but five of these were borderline negative by EIA, having values of > 5 and < 10 fmol/mg protein. Ten tumours were IHA negative and EIA+; four of these tumours were completely negative by IHA in the section studied. A further IHA assay, carried out on the 17 tumour mismatches with H222 antibody, showed that three tumours remained substantially discordant. These three tumours were strongly positive with the 1D5 antibody and negative with the H222 antibody. Two of these discordant tumours were of the rare ER negative and PgR positive phenotype and may contain oestrogen receptor that is of biological interest but which lacks the hormone binding epitope.
CONCLUSIONS: The concordance between the classic enzyme immunoassay technique and the new immunohistochemical method on paraffin wax embedded sections was good. Moreover, the IHA technique using the 1D5 antibody against the N-terminal was easily reproducible. This technique may allow oestrogen receptor content to be determined in large cohorts of patients in whom archival tumour material is available.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962603      PMCID: PMC502173          DOI: 10.1136/jcp.47.10.900

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Immunostaining of estrogen receptor in paraffin sections of breast carcinomas using monoclonal antibody D75P3 gamma: effects of fixation.

Authors:  C M De Rosa; L Ozzello; G L Greene; D V Habif
Journal:  Am J Surg Pathol       Date:  1987-12       Impact factor: 6.394

2.  Monoclonal antibody technique for detection of estrogen receptors in human breast cancer: greater sensitivity and more accurate classification of receptor status than the dextran-coated charcoal method.

Authors:  S M Thorpe
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

3.  Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Use of DNase pretreatment to enhance sensitivity of the reaction.

Authors:  I P Shintaku; J W Said
Journal:  Am J Clin Pathol       Date:  1987-02       Impact factor: 2.493

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Relationship between radioligand binding assay, immunoenzyme assay and immunohistochemical assay for estrogen receptors in human breast cancer and association with tumor differentiation.

Authors:  J Andersen; S M Bentzen; H S Poulsen
Journal:  Eur J Cancer Clin Oncol       Date:  1988-03

6.  The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays.

Authors:  J Andersen; S M Thorpe; W J King; C Rose; I Christensen; B B Rasmussen; H S Poulsen
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

7.  Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER).

Authors:  T al Saati; S Clamens; E Cohen-Knafo; J C Faye; H Prats; J M Coindre; J Wafflart; P Caverivière; F Bayard; G Delsol
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

8.  Monoclonal antibodies as probes for estrogen receptor detection and characterization.

Authors:  G L Greene; E V Jensen
Journal:  J Steroid Biochem       Date:  1982-03       Impact factor: 4.292

9.  Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections.

Authors:  A Shimada; S Kimura; K Abe; K Nagasaki; I Adachi; K Yamaguchi; M Suzuki; T Nakajima; L S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

10.  Variation of receptor status in cancer of the breast.

Authors:  R N Harland; D M Barnes; A Howell; G G Ribeiro; J Taylor; R A Sellwood
Journal:  Br J Cancer       Date:  1983-04       Impact factor: 7.640

View more
  11 in total

1.  Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.

Authors:  A Huang; E R Leygue; L Snell; L C Murphy; P H Watson
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Lymphatic-targeted therapy following neoadjuvant chemotherapy: a promising strategy for lymph node-positive breast cancer treatment.

Authors:  Jianghao Chen; Qing Yao; Hui Wang; Bo Wang; Juliang Zhang; Ting Wang; Yonggang Lv; Zenghui Han; Ling Wang
Journal:  Med Oncol       Date:  2015-05-26       Impact factor: 3.064

3.  Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening.

Authors:  A Rhodes; B Jasani; A J Balaton; D M Barnes; K D Miller
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

4.  Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome.

Authors:  Jin Yeong Kim; Haengseok Song; Hyunjoo Kim; Hee Jung Kang; Jin Hyun Jun; Sung Ran Hong; Mi Kyoung Koong; In Sun Kim
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

5.  Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy.

Authors:  J F Zhang; C Hu; Y Geng; J Selm; S B Klein; A Orazi; M W Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

Authors:  S Detre; G Saclani Jotti; M Dowsett
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

7.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.

Authors:  D M Barnes; W H Harris; P Smith; R R Millis; R D Rubens
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeated Implantation Failure (RIF).

Authors:  Youngsok Choi; Hye-Ryun Kim; Eun Jin Lim; Miseon Park; Jung Ah Yoon; Yeon Sun Kim; Eun-Kyung Kim; Ji-Eun Shin; Ji Hyang Kim; Hwang Kwon; Haengseok Song; Dong-Hee Choi
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

9.  Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.

Authors:  Jianghao Chen; Qing Yao; Dong Li; Juliang Zhang; Ting Wang; Ming Yu; Xiaodong Zhou; Yi Huan; Jing Wang; Ling Wang
Journal:  BMC Cancer       Date:  2013-05-21       Impact factor: 4.430

10.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

Authors:  C D Archer; M Parton; I E Smith; P A Ellis; J Salter; S Ashley; G Gui; N Sacks; S R Ebbs; W Allum; N Nasiri; M Dowsett
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.